Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop
New York, Jan 12, 2026, 15:14 (EST) — Regular session Mesoblast Ltd’s shares on the U.S. market dropped roughly 11% Monday, sliding to $18.64 in afternoon trading after hitting $20.14 earlier. The Australian biotech’s stock has seen sharp swings since it started highlighting early commercial progress for its main cell therapy. The pullback is significant since Mesoblast has moved beyond…